Overview

Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. Imaging agents, such as fluoroethyltyrosine, may help doctors see the tumor better during a positron emission tomography (PET) scan.
Phase:
Phase 2
Details
Lead Sponsor:
Thomas Hope